TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06298448

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory experiments before and after mepolizumab treatment
Description: Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory experiments before and after mepolizumab treatment
Description: Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory experiments before and after mepolizumab treatment
Description: Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory experiments before and after mepolizumab treatment
Description: Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory experiments before and after mepolizumab treatment
Description: Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome
Study: NCT06111378

Intervention type: DIETARY_SUPPLEMENT
Intervention: fish oil
Description: fish oil

Intervention type: DIETARY_SUPPLEMENT
Intervention: linseed oil
Description: linseed oil

Intervention type: DIETARY_SUPPLEMENT
Intervention: walnut oil
Description: walnut oil
Study: NCT06393309

Intervention type: DRUG
Intervention: Levetiracetam
Description: Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam

Intervention type: DRUG
Intervention: Sodium valproate
Description: Patients with idiopathic generalized epilepsy who were under treatment with valproate
Study: NCT05947474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORB-011
Description: Drug: ORB-011 is dosed via IV infusion
Study: NCT06143748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Description: Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
Study: NCT06485310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation for psychological support
Description: Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice
Study: NCT05142267

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: Naloxone
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Study: NCT06185660

Intervention type: DRUG
Intervention: sodium zirconium cyclosilicate (SZC)
Description: sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.

Intervention type: DRUG
Intervention: sodium zirconium cyclosilicate (SZC)
Description: sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.

Intervention type: DRUG
Intervention: sodium zirconium cyclosilicate (SZC)
Description: sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
Study: NCT05061251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 2402234
Description: Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
Study: NCT03958344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone + Betamethason
Description: A compound long acting and short acting injectable steroid
Study: NCT05034705

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional suction system
Description: This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental aerosol box with modified high volume evacuation system
Description: The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
Study: NCT05229289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant
Study: NCT05698173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
Study: NCT06449833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozein and Metformin
Description: The experimental group will be treated with 10mg Henagliflozein and Metformin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin and Metformin
Description: The control group will be treated with 5mg Linagliptin and Metformin.
Study: NCT06164626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction
Description: extraction: in all groups, extraction will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction
Description: extraction: in all groups, extraction will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction
Description: extraction: in all groups, extraction will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction
Description: extraction: in all groups, extraction will be performed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plenum® OSShp and Plenum® Guide
Description: extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plenum® OSShp and Plenum® Guide
Description: extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
Study: NCT04947800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + Lv7/Gb26
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + Lv7/Gb26
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + Lv7/Gb26
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
Study: NCT06576856

Intervention type: OTHER
Intervention: This is an observational study, no intervention is anticipated.
Description: There is no intervention. This is an observational study.

Intervention type: OTHER
Intervention: This is an observational study, no intervention is anticipated.
Description: There is no intervention. This is an observational study.
Study: NCT05440110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active and active TBS
Description: The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
Study: NCT05440110

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham and active TBS
Description: The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
Study: NCT06396026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 tablets
Description: Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.
Study: NCT06576856

Intervention type: OTHER
Intervention: This is an observational study, no intervention is anticipated.
Description: There is no intervention. This is an observational study.
Study: NCT06575491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular approach
Description: Patients submitted to Supraclavicular approach for ultrasound-guided Subclavian veinous catheterization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular approach
Description: Patients submitted to Infraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
Study: NCT05497310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Patients will receive ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: Patients will receive ATRA 25/mg/m2/day for 28 continuous days without interruption.
Study: NCT05601453

Intervention type: PROCEDURE
Intervention: Elective redo transcatheter aortic valve implantation (redo-TAVI)
Description: Elective redo-TAVI procedure with the intention to treat the patient with a SAPIEN family valve implantation (currently the only registered medical devices for redo-TAVI use)
Study: NCT05484999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals
Description: 12 weeks of medically tailored meals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meals
Description: 12 weeks of medically tailored meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals + Social Support
Description: 12 weeks of medically tailored meals and12 weeks of social media based support

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Waitlist Control Group (no intervention for first 4 months and then receive MamaMeals between 16-20 weeks postpartum)
Study: NCT05149625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: continuous glucose monitoring device
Study: NCT05043974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry immersion
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
Study: NCT05350657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: 2 week isocaloric, high protein and low carbohydrate ketogenic diet
Study: NCT05907564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Use of Aventus Thrombectomy System to treat pulmonary embolism
Study: NCT06577480

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06512285

Intervention type: DIAGNOSTIC_TEST
Intervention: Continuous Pulse Oximetry
Description: The patient will wear a continuous pulse oximeter after their adenotonsillectomy surgery until the following morning. This will record continuous pulse oximetry data to allow for analysis of any desaturations in the first night following the surgery. This study is observational only and this data will not be used to impact any treatment
Study: NCT06244953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIER-HF-PC
Description: The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patient continues on clinical care by his/her cardiologist. If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.
Study: NCT06576011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified Social Norms Marketing Campaign
Description: This intervention is a gamified social norms marketing campaign (SNMC) primarily disseminated via advertisements on Instagram. These advertisements will invite students to participate in a game about student life at their university, during which misperceived alcohol norms will be corrected. The gamified SNMC spans the first full six weeks of students' first fall semester in college and includes three rounds of play. Round one occurs during the first two weeks, round two during the third and fourth weeks, and round three during the fifth and sixth weeks. In the game, participants are asked to identify whether normative facts related to a variety of topics are true or false. Correct feedback is then provided, intended to reinforce accurate norms related to alcohol use, which are embedded alongside other facts about college life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Norms Marketing Campaign
Description: This intervention is a social norms marketing campaign that is primarily delivered via advertisements on Instagram. These advertisements will contain normative facts related to student life at their university, during which misperceived alcohol norms will be corrected.
Study: NCT05660161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofracture
Description: The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care.
Study: NCT05702931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 14 MG [Rybelsus]
Description: At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT06205043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimSearch programming algorithm software
Description: This is an algorithm based method to program deep brain stimulation in patients of Parkinson's disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinician based programming
Description: This is Standard of Care programming performed for patients undergoing deep brain stimulation for Parkinson's disease